Loading
A phase 2 trial of EIK1001, Pembrolizumab, Pemetrexed and Carboplatin in non-small-cell lung cancer, run by Eikon Therapeutics, active and no longer recruiting.
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC is a phase 2 interventional study registered as NCT06246110 by Eikon Therapeutics, with 70 participants enrolled, started 2024-02-06 and due to reach its primary completion in 2026-12. Interventions recorded: EIK1001, Pembrolizumab, Paclitaxel, Pemetrexed and Carboplatin.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pemetrexed, Carboplatin, Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Pemetrexed, Carboplatin, Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Pemetrexed, Carboplatin, Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Pemetrexed, Carboplatin, Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Pemetrexed, Carboplatin, Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Pemetrexed, Carboplatin, Pembrolizumab, Non-small-cell lung cancer and the tag pipeline.
Shares Pemetrexed, Carboplatin, Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Pemetrexed, Carboplatin, Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/